Search results for "Tumor-Infiltrating"

showing 10 items of 78 documents

Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX ch…

2013

The GOLFIG-2 phase III trial was designed to compare the immunobiological activity and antitumor efficacy of GOLFIG chemoimmunotherapy regimen with standard FOLFOX-4 chemotherapy in frontline treatment of metastatic colorectal cancer (mCRC) patients. This trial was conceived on the basis of previous evidence of antitumor and immunomodulating activity of the GOLFIG regimen in mCRC. GOLFIG-2 is a multicentric open/ label phase III trial (EUDRACT: 2005-003458-81). Chemo-naive mCRC patients were randomized in a 1:1 ratio to receive biweekly standard FOLFOX-4 or GOLFIG [gemcitabine (1000 mg/m 2, day 1); oxaliplatin (85 mg/m2, day 2); levofolinate (100 mg/m2, days 1-2), 5-fluorouracil (5-FU) (400…

OncologyMaleCancer ResearchGranulocyte-macrophage-colonystimulating- factorOrganoplatinum Compoundsmedicine.medical_treatmentLeucovorinColorectal NeoplasmGastroenterologyDeoxycytidineFOLFOXAldesleukinPhase iii trialAntineoplastic Combined Chemotherapy ProtocolsImmunology and AllergyMedicineChemoimmunotherapyNeoplasm MetastasisAged 80 and overAldesleukinMiddle AgedNeoplasm MetastasiOxaliplatinColorectal carcinomaTreatment OutcomeFluorouracilFemaleFluorouracilColorectal NeoplasmsHumanmedicine.drugAdultmedicine.medical_specialtyImmunologyLymphocytes Tumor-InfiltratingChemoimmunotherapyInternal medicineHumansAgedPharmacologyChemotherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryOrganoplatinum CompoundGranulocyte-Macrophage Colony-Stimulating FactorGemcitabineGemcitabineOxaliplatinRegimenInterleukin-2Neoplasm GradingbusinessJournal of immunotherapy (Hagerstown, Md. : 1997)
researchProduct

Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies.

2008

During the last two decades, considerable efforts have been made to improve the prevention, early diagnosis and therapy of colorectal cancer by gaining enhanced insights into disease-specific pathogenesis. Along these lines, tumor-infiltrating immune cells turned out to be critical indicators for an efficient antitumor immune response and the number and type of tumor-infiltrating immune cells determined the resulting tumor prognosis. This review aims to describe the prognostic relevance of the different subsets of tumor-infiltrating immune cells and highlights their specific function in the complex process of immune system-mediated rejection of colorectal cancer cells. Considering the clini…

Oncologymedicine.medical_specialtyColorectal cancermedicine.medical_treatmentT cellAntineoplastic AgentsCancer VaccinesT-Lymphocytes RegulatoryPathogenesisImmune systemLymphocytes Tumor-InfiltratingAntigenAntigens NeoplasmInternal medicinemedicineBiomarkers TumorHumansPharmacology (medical)biologybusiness.industryMacrophagesAntibodies MonoclonalImmunotherapyDendritic Cellsmedicine.diseasePrognosisKiller Cells NaturalCytokinemedicine.anatomical_structureEarly DiagnosisOncologybiology.proteinImmunotherapyAntibodybusinessColorectal NeoplasmsImmunologic MemoryExpert review of anticancer therapy
researchProduct

Immune cell score, PD-L1 expression and prognosis in esophageal cancer.

2021

Esophageal cancer (EC) is the ninth most common cancer worldwide and the sixth leading cause of cancer death [1]. Despite improvements in the treatment of EC, the general outcome remains poor [2–4]...

Oncologymedicine.medical_specialtyEsophageal NeoplasmsCellMEDLINEB7-H1 Antigen030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineImmune systemLymphocytes Tumor-InfiltratingInternal medicinemedicineBiomarkers TumorHumansRadiology Nuclear Medicine and imagingCancer deathbusiness.industryCancerHematologyGeneral MedicineEsophageal cancermedicine.diseasePrognosismedicine.anatomical_structureOncology030220 oncology & carcinogenesisPd l1 expressionbusinessActa oncologica (Stockholm, Sweden)
researchProduct

2015

Background Immunotherapy can become a crucial therapeutic option to improve prognosis for lung cancer patients. First clinical trials with therapies targeting the programmed cell death receptor PD-1 and its ligand PD-L1 have shown promising results in several solid tumors. However, in lung cancer the diagnostic, prognostic and predictive value of these immunologic factors remains unclear. Method The impact of both factors was evaluated in a study collective of 321 clinically well-annotated patients with non-small lung cancer (NSCLC) using immunohistochemistry. Results PD-1 expression by tumor infiltrating lymphocytes (TILs) was found in 22%, whereas tumor cell associated PD-L1 expression wa…

Oncologymedicine.medical_specialtyMultidisciplinaryTumor-infiltrating lymphocytesbusiness.industrymedicine.diseaseExact testBreast cancerInternal medicineCarcinomamedicineAdjuvant therapyAdenocarcinomabusinessLung cancerSurvival ratePLOS ONE
researchProduct

The prognostic impact of PD1 and PDL1 expression in non-small cell lung cancer

2015

Introduction: To improve the prognosis of lung cancer patients, immunotherapy is expected to become a powerful therapeutic option. Several clinical studies demonstrate a positive prognostic effect of a targeted therapy against the programmed cell death receptor PD1 and its ligand PDL1 in solid tumors. For non-small lung cancer (NSCLC) however, the diagnostic, prognostic and predictive impact of these factors needs to be clarified. Materials and Methods: Immunohistochemistry was performed to evaluate the expression profile of PD1 and PDL1 in 398 NSCLC patients (median age: 66 years, 78% male sex, 45% squamous cell carcinoma (SCC) histology). Statistical analysis included Fisher9s Exact test,…

Oncologymedicine.medical_specialtyPathologybusiness.industryTumor-infiltrating lymphocytesmedicine.medical_treatmentContext (language use)Immunotherapymedicine.diseaseTargeted therapyLog-rank testExact testInternal medicinemedicineAdjuvant therapybusinessLung cancer11.1 Lung Cancer
researchProduct

Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?

2019

International audience; In recent years, multiple strategies for eliciting anti-tumor immunity have been developed in different clinical studies. Currently, immunotherapy was clinically validated as effective treatment option for many tumors such as melanoma, non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC). Some surface receptors of immune cells, called immune checkpoint receptors, may inhibit activity of proinflammatory lymphocytes, following binding with specific ligands. Cancer cells exploit these mechanisms to inactivate tumor-infiltrating lymphocytes (TILs) to escape from immunosurveillance. Among the different tumor-infiltrating immune cell populations, including leu…

PD-L10301 basic medicinePrognosiSettore MED/06 - Oncologia Medica[SDV]Life Sciences [q-bio]medicine.medical_treatmentImmunologyPredictive significance[SDV.CAN]Life Sciences [q-bio]/Cancerchemical and pharmacologic phenomenaBiology03 medical and health sciencesLymphocytes Tumor-Infiltrating0302 clinical medicineImmune systemNeoplasmsImmune suppressionPD-1Biomarkers TumormedicineAnimalsHumansTumor microenvironmentTumor-infiltrating lymphocytesMelanomaImmunotherapyPrognosismedicine.diseaseImmune checkpoint3. Good healthImmunosurveillance030104 developmental biologyTumor microenvironment030220 oncology & carcinogenesisCancer cellTumor immunologyCancer researchImmunotherapy[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyTumor-infiltrating lymphocytes (TILs)Cellular Immunology
researchProduct

Surface phenotype and functions of tumor-infiltrating dendritic cells: CD8 expression by a cell subpopulation.

1993

Although the function and significance of tumor-infiltrating dendritic cells (TIDC) in the immune response to tumor have never been clearly demonstrated, their location suggests that they play a critical role in the presentation of tumor antigen to specific T cells. We studied the morphological and functional characteristics of interstitial dendritic cells (DC) located inside tumors obtained by injection of cancer cells into syngeneic rats. Single and double immunostaining of tumor sections revealed a dense network of cells which expressed class II major histocompatibility complex (MHC II) molecules. Cell morphology and surface markers were characteristic of DC populations in other tissues.…

Pathologymedicine.medical_specialtyCD8 AntigensImmunologyAntigen presentationAntigen-Presenting CellsBiologyMajor histocompatibility complexCell morphologyLymphocytes Tumor-InfiltratingAntigenAntigens NeoplasmmedicineImmunology and AllergyAnimalsAntibodies MonoclonalRats Inbred StrainsDendritic cellDendritic CellsNeoplasms ExperimentalMolecular biologyTumor antigenRatsPhenotypeCancer cellbiology.proteinCD8European journal of immunology
researchProduct

Study of the immunophenotype of the inflammatory cells in melanomas with regression and halo nevi.

2015

Abstract The pathogenesis and prognostic implications of regression in melanoma are not well understood. It has traditionally been considered an immunologically mediated phenomenon. Improvement in the knowledge of the mechanisms that lead to regression may prove to be of great value in an era in which treatments oriented to the augmentation of the host's immunity against melanoma have demonstrated excellent clinical results. This study was designed to improve the understanding of the mechanisms underlying melanoma regression and the differences between similar situations in benign melanocytic nevus. The study sample consisted of 77 lesions: 62 melanomas and 15 halo nevi. The following marke…

Pathologymedicine.medical_specialtySkin NeoplasmsDermatologyT-Lymphocytes RegulatoryPathology and Forensic MedicineImmunophenotypingImmunophenotypingLymphocytes Tumor-InfiltratingPredictive Value of TestsBiomarkers TumorMedicineCytotoxic T cellHumansBenign melanocytic nevusneoplasmsMelanomaInflammationbiologybusiness.industryMelanomaFOXP3General Medicinemedicine.diseaseFibrosisImmunohistochemistryPhenotypeGranzymeNeoplasm Regression Spontaneousbiology.proteinInterleukin-3 receptorbusinessCD8Nevus HaloT-Lymphocytes CytotoxicThe American Journal of dermatopathology
researchProduct

Integrated multi-omics investigations of metalloproteinases in colon cancer: Focus on MMP2 and MMP9

2021

Colorectal cancer (CRC) develops by genetic and epigenetic alterations. However, the molecular mechanisms underlying metastatic dissemination remain unclear and could benefit from multi-omics investigations of specific protein families. Matrix metalloproteinases (MMPs) are proteolytic enzymes involved in ECM remodeling and the processing of bioactive molecules. Increased MMP expression promotes the hallmarks of tumor progression, including angiogenesis, invasion, and metastasis, and is correlated with a shortened survival. Nevertheless, the collective role and the possible coordination of MMP members in CRC are poorly investigated. Here, we performed a multi-omics analysis of MMP expression…

ProteomicsMMP2Epithelial-Mesenchymal TransitionQH301-705.5Colorectal cancerBioinformaticsKaplan-Meier EstimateBiologyMatrix metalloproteinaseMMP9ArticleCatalysisEpigenesis GeneticMetastasisCohort StudiesInorganic ChemistryLymphocytes Tumor-InfiltratingmedicineHumansEpithelial–mesenchymal transitionBiology (General)Physical and Theoretical ChemistrySettore BIO/06 - Anatomia Comparata E CitologiaQD1-999Molecular BiologySpectroscopyTissue Inhibitor of Metalloproteinase-2Functional analysisMMP9Organic ChemistryProteolytic enzymesGeneral Medicinemedicine.diseasePrognosisComputer Science ApplicationsColon cancerExtracellular MatrixGene Expression Regulation NeoplasticChemistryMatrix metalloproteinasesMatrix Metalloproteinase 9Tumor progressionCase-Control StudiesColonic NeoplasmsCancer researchMatrix Metalloproteinase 2Gene expressionMMP2
researchProduct

Distribution, function and predictive value of tumor-infiltrating γδ T lymphocytes

2013

Although γδ T cells are known to exert both tumor-preventing and tumor-promoting activity, there is still little information on the functional characteristics and clinical significance of γδ T cells isolated from the tumor site. In a recent study, we have investigated the distribution of different γδ T-cell populations in melanoma and their impact on disease outcome.

Settore MED/04 - Patologia GeneraleTumor-infiltrating lymphocytesDisease outcomebusiness.industryMelanomaImmunologymedicine.diseasePredictive valueTumor siteγδ T cellscytokinesOncologytumor-infiltrating lymphocytesγδ T cells cytokines cytotoxicity melanoma tumor-infiltrating lymphocytesImmunologymedicinemelanomaImmunology and AllergycytotoxicityClinical significanceCytotoxicitybusinessAuthor's ViewOncoimmunology
researchProduct